GSK has agreed to acquire US-based biotech firm RAPT Therapeutics in a deal valued at $2.2 billion, strengthening the British drugmaker’s pipeline in immunology and inflammation.
Under the terms of the agreement, GSK will pay $X per share in cash, representing a significant premium to RAPT’s recent trading price. The acquisition gives GSK control of RAPT’s lead drug candidate, which targets inflammatory and immune-mediated diseases and is seen as having strong potential in areas of high unmet medical need.
RAPT, a clinical-stage biotechnology company, has been developing therapies designed to modulate immune responses, with a particular focus on conditions such as inflammatory bowel disease and other autoimmune disorders. GSK said the deal aligns with its strategy of expanding its portfolio through targeted acquisitions that complement its in-house research.
Emma Walmsley, GSK’s chief executive, said the transaction would “accelerate our ambition to deliver innovative medicines for patients with immune-driven diseases,” adding that RAPT’s science and expertise would strengthen GSK’s long-term growth prospects.
The acquisition comes amid intensifying competition among large pharmaceutical companies to secure promising biotech assets, as drugmakers look to replenish pipelines and offset the impact of future patent expiries. For RAPT, the deal provides the scale and resources needed to advance its therapies through late-stage clinical trials and, potentially, to market.
The transaction is expected to close later this year, subject to regulatory approvals and customary closing conditions.
Leave a Comment